btk-in-5

BTK-IN-5, a covalent inhibitor of Bruton's tyrosine kinase (BTK), is designed for treating cardiovascular diseases, respiratory diseases, inflammation, and diabetes.

JAK3 BTK-IN-5 is a potent inhibitor of JAK3 BTK, crucial targets in autoimmune diseases. Inhibiting the BTK JAK3 signaling pathway simultaneously has a synergistic effect, enhancing its potential research value for JAK3 kinase and or BTK-related diseases.

Lenalidomide-6-F-piperidine-C2-Pip-C-COOH acts as a linker and an E3 ligase ligand for PROTACBTKDegrader-5, utilized in the study of malignant lymphomas.

Piperidine-C2-Pip-C-COOH serves as a linker for PROTAC BTK Degrader-5, significantly enhancing metabolic stability for use in cancer research.

A-410099.1, also known as amine-Boc, serves as a functionalized IAP ligand instrumental in the synthesis of PROTACs, including those targeting BTK (specifically PROTACs 4 and 5).

A 410099.1, amine-Boc hydrochloride, serves as a functionalized IAP (Inhibitor of Apoptosis Proteins) ligand instrumental in the synthesis of PROTACs (Proteolysis Targeting Chimeras), notably those targeting BTK (Bruton's Tyrosine Kinase), including PROTACs 4 and 5.

BTK-IN-10 is a potent inhibitor of BTK, effective against both wild-type BTK (IC50<5 nM) and mutant BTK (C481S) (IC50<5 nM).

PROTAC BTK Degraders-5 (Compound 3e) is a selective Bruton's tyrosine kinase (BTK) degrader with a DC50 of 7.0 nM in JeKo-1 cells, demonstrating specificity by not affecting CRBN neosubstrates. It also exhibits antiproliferative effects on various lymphoma cell lines, underscoring its potential application in chronic lymphoid malignancies research.

BTK-IN-27 (example 8), a potent BTK inhibitor with an IC50 of 0.2 nM, demonstrates anti-proliferative effects in TMD8 cells with an IC50 of less than 5 nM. It is suitable for the research of various conditions including cancer, lymphoma, leukemia, and immunological diseases [1].